MOLECULAR PATHOLOGY OF GLIOMAS

Project: Research project

Project Details

Description

Determining diagnosis, assessing prognosis, and assigning appropriate
therapy for patients with gliomas has traditionally relied on
pathological and clinical factors. These factors include the age, sex,
and performance status as well as tumor histologic type, pathologic
grade, and specific location. Some of these factors are easy to assess
while others, especially histologic type and grade, can be difficult and
depend upon the interpretation of a skilled neuropathologist.

Molecular genetic, cytogenetic, flow cytometric, and immunohistochemical
factors have been used to assess many solid tumors including gliomas.
During the initial grant period at Mayo several potential factors which
may be useful in the classification of glial tumors have been identified
The first goal of the next study period is: to determine if such factor
can be used to classify astrocytic tumors of favorable and poor
prognosis. The second goal is to develop markers which will reliably
differentiate astrocytomas, oligodendrogliomas, and mixed
oligoastrocytomas. Several groups of tumor specimens will be available
to help achieve these goals: 1) the set of frozen gliomas prospectively
obtained at Mayo during the initial and renewal project period, 2) sets
of paraffin-embedded gliomas from patients entered on previous and
current prospective clinical trials of the North Central Cancer
Treatment Group (NCCTG) and the Radiation Therapy Oncology Group (RTOG),
and 3) a large series of retrospectively ascertained paraffin-embedded
gliomas previously treated at Mayo but not part of the preceding two
groups.

The specific aims of this project are to: 1) to evaluate the diagnostic
and prognostic relevance of alterations of specific chromosomes and
chromosomal regions detected by polymerase chain reaction (PCR) analysis
of microsatellite repeats and fluorescent in situ hybridization (FISH).
2) To evaluate the diagnostic and prognostic relevance of DNA ploidy by
flow cytometric analysis and to compare this analysis with ploidy
determination by FISH. 3) To assess the diagnostic and prognostic
relevance of various markers of cellular proliferation and cellular
function including flow cytometric determination of %S-phase, %G2M, and
immunohistochemical evaluation of PCNA, Ki67, and p53. 4) To evaluate
molecular markers proposed by the other institutions supported by this
cooperative agreement and to share techniques, tissues, and expertise
with these institutions.

The long-term objective of this project is to assess and utilize
molecular markers to more accurately classify and grade gliomas and thus
improve the prediction of prognosis and the assignment of optimal therap
for patients with these tumors.
StatusNot started

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.